From December 12th to 15th, the 11th Annual Meeting of CSSCR was successfully held at the Guangzhou Yuexiu International Congress Center. Experts and scholars from the domestic stem cell field gathered to discuss stem cell research and its translation, advancing the development of stem cell and regenerative medicine in China. The conference featured seven specialized sub-sessions on cutting-edge research in stem cells and regenerative medicine, providing a highly professional platform for st em cell researchers and individuals from various sectors interested in stem cell science.
bioGenous Chief Scientist, Professor ZHAO Bing from Fudan University, delivered a special report titled "Organoid Models of Infectious Diseases and Developmental Defects" at the "Stem Cell Simulation of Development and Disease" session.
In his presentation, Professor ZHAO Bing emphasized that organoids are excellent models for studying disease mechanisms and drug screening. Human organoids can address various viral pathogenesis mechanisms. For example, liver organoids can be used to study the mechanisms of liver damage caused by COVID-19 infection: after the virus efficiently infects human-derived cholangiocyte organoids, it leads to the death of some cholangiocyte epithelial cells and induces cholangiocyte dysfunction. Additionally, organoids assist in the development of potential drugs for human hepatocellular carcinoma.
bioGenous showcased standardized culture kits for lung cancer organoids, including small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma, as well as high-activity organoid culture growth factors at the exhibition.
bioGenous shone brightly at this exhibition, attracting numerous experts and scholars to its booth to discuss organoid technology and its translation, sharing experiences on the value of organoid models and future development directions. Many teachers, students, and business partners interested in organoids also visited the booth to inquire about organoid technology and products, expressing intentions for further communication and collaboration in the future.
About bioGenous
bioGenous is a leading one-stop provider of organoid technology products and solutions. The company has been deeply involved in basic organoid research and translational applications for many years. Since 2016, bioGenous has gradually established and perfected a full range of upstream organoid technologies, covering multiple tissue and tumor organoid culture, development and disease modeling, genetic manipulation, efficacy and toxicity evaluation, animal transplantation, multiomics atlas of organoids, organoid precision medicine, automated operations, and more. In 2020, to meet the explosive global demand for CDMO services in organoid technology, bioGenous built a 2,000-square-meter production facility that complies with international GMP standards for biopharmaceuticals. The company is committed to creating a standardized and modular CDMO service platform for basic biological and medical research, drug development, and precision medicine, leading a revolution in biomedical models and advancing human health.
